Logo

SION

Sionna Therapeutics, Inc.

SION

Sionna Therapeutics, Inc. • NASDAQ
$43.57 ▼ -0.50% (-0.22)
Market Cap $1.94 B
52w High $45.00
52w Low $7.25
Dividend Yield 0%
P/E -24.21
Volume 222.84K
Outstanding Shares 44.63M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $23.705M ▲ $-20.278M ▼ 0% $-0.456 ▼ $-20.178M ▼
Q2-2025 $0 $21.759M ▲ $-18.068M ▼ 0% $-0.41 ▼ $-17.921M ▲
Q1-2025 $0 $19.659M ▲ $-16.482M ▼ 0% $-0.374 ▼ $-19.228M ▼
Q4-2024 $0 $18.133M ▲ $-15.848M ▼ 0% $-0.359 ▼ $-17.966M ▼
Q2-2024 $0 $11.126M $-8.552M 0% $-0.194 $-8.386M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $248.329M ▼ $339.27M ▼ $17.602M ▲ $321.668M ▼
Q2-2025 $262.571M ▼ $352.048M ▼ $15.619M ▼ $336.429M ▼
Q1-2025 $269.666M ▲ $369.674M ▲ $17.905M ▼ $351.769M ▲
Q4-2024 $147.538M ▲ $185.752M ▼ $349.465M ▲ $-163.713M ▼
Q3-2024 $137.474M $197.265M $345.814M $-148.549M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-20.278M ▼ $-15.23M ▲ $23.102M ▲ $1.974M ▲ $9.846M ▲ $-15.317M ▲
Q2-2025 $-18.068M ▼ $-18.153M ▼ $-23.245M ▲ $-312K ▼ $-41.71M ▼ $-18.153M ▼
Q1-2025 $-16.482M ▼ $-16.288M ▼ $-141.194M ▼ $202.389M ▲ $44.907M ▲ $-16.374M ▼
Q4-2024 $-15.848M ▼ $-11.781M ▼ $15.228M ▲ $-1.408M ▼ $2.039M ▲ $-11.808M ▼
Q2-2024 $-8.552M $-10.145M $-28.621M $38K $-38.728M $-10.145M

Five-Year Company Overview

Income Statement

Income Statement Sionna is clearly still in the classic early-stage biotech phase: no product revenue yet and steady research-driven losses. The operating and net losses have been widening gradually over the last few years, which fits with a company pushing multiple drug candidates through early clinical trials. The absence of revenue means results are highly sensitive to R&D and overhead choices, rather than to market demand or pricing. Overall, the income statement reflects a company investing heavily in science today with the hope of future payoff, rather than one focused on near-term profitability.

Balance Sheet

Balance Sheet The balance sheet is lean and research-focused, with relatively small total assets and only modest cash on hand in the historical periods shown. Equity is negative, which mainly reflects accumulated losses typical of a young biotech that has spent more on R&D than it has raised historically. Debt levels appear low, so the company has not leaned heavily on borrowing, which reduces financial strain from interest but increases reliance on raising equity. The narrative about a large IPO adding meaningful cash suggests the post-IPO balance sheet is likely much stronger than the backward-looking figures indicate, but that new capital will gradually be consumed by ongoing trials.

Cash Flow

Cash Flow Cash flows show a consistent pattern of money flowing out to fund operations and essentially nothing going into long-lived assets, which is what you’d expect for a science-first biotech without manufacturing or commercial infrastructure yet. Operating cash burn has been fairly stable to slightly increasing, implying disciplined but growing R&D activity as more programs move through the clinic. With no capital spending to speak of, nearly all cash use is tied directly to research and corporate expenses, making the burn rate a key figure to watch against available cash. Over time, continued trial expansion will likely put upward pressure on cash outflows, even with the IPO boost.

Competitive Edge

Competitive Edge Sionna is aiming at a very specific and valuable niche: improving treatment for cystic fibrosis in a space currently dominated by a single large incumbent. Its differentiator is a distinct scientific angle—targeting a part of the CFTR protein that current drugs do not directly stabilize—which could make its therapies complementary to or more effective than existing options. If its drugs work as hoped, the company could address patients who do not fully benefit from current standard-of-care therapies and potentially participate in combination regimens. The flip side is that Sionna is competing in a highly specialized, data-driven market where the existing leader is well-entrenched, so success will depend heavily on clear, superior clinical results and smart partnering or commercialization strategies.

Innovation and R&D

Innovation and R&D Innovation is the core of Sionna’s story. The company is building a platform of drug candidates that all aim to more fully normalize the defective protein that causes cystic fibrosis, rather than just partially correcting its function. Its lead NBD1-stabilizing molecules, along with complementary modulators licensed from a large pharmaceutical company, create the possibility of proprietary combinations that could stand out in both efficacy and breadth of patients served. Multiple programs have already reached human studies, which is an important de-risking step, but upcoming mid-stage trials will be the real test of whether this scientific concept can translate into meaningful clinical benefit.

Summary

Sionna today is a pre-revenue, clinically focused biotech with financials that reflect steady investment and rising losses in pursuit of high-impact cystic fibrosis therapies. The historical balance sheet and cash flows show a small, research-heavy organization that has been operating efficiently but at a predictable cash burn, now bolstered by a sizeable IPO that is expected to fund several years of development. Strategically, its differentiated scientific approach and pipeline breadth give it a credible shot at reshaping or augmenting the current standard of care, particularly through combination treatments. The main uncertainties center on clinical outcomes, regulatory paths, competitive responses from the current market leader, and the company’s ability to convert scientific promise into durable commercial value before its cash runway narrows.

NEWS

November 24, 2025 · 7:00 AM UTC

Sionna Therapeutics to Participate in Upcoming December Investor Conferences

Read more

November 5, 2025 · 7:00 AM UTC

Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Read more

November 4, 2025 · 8:00 AM UTC

Sionna Therapeutics to Participate in Upcoming November Investor Conferences

Read more

October 24, 2025 · 1:15 PM UTC

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Read more

October 21, 2025 · 7:00 AM UTC

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Read more